What is Imperative Care?
Imperative Care operates at the intersection of medical technology, robotics, and digital health. The company specializes in the development and commercialization of connected innovations designed to improve clinical outcomes for patients affected by stroke and other ischemic vascular diseases. By integrating interventional solutions with advanced digital health tools, the firm addresses the entire patient journey, from initial diagnosis to recovery. Its market position is defined by a commitment to enhancing treatment effectiveness through technological precision, effectively positioning the company as a vital player in the global medtech landscape.
How much funding has Imperative Care raised?
Imperative Care has raised a total of $445M across 3 funding rounds:
Series C
$85M
Series D
$260M
Debt
$100M
Series C (2019): $85M with participation from Ascension Ventures, 3H Health Investment, Ally Bridge Group, Rock Springs Capital, Delos Capital, Incept LLC, and Bain Capital
Series D (2021): $260M led by Ally Bridge Group, Bain Capital Life Sciences, D1 Capital Partners, Innovatus Capital Partners, and HealthCor Investments
Debt (2026): $100M supported by Catalio Capital Management, Bain Capital, Longaeva Books, Ally Bridge Group, Brown Advisory, Elevage Medical Technologies, and Perceptive Advisors
Key Investors in Imperative Care
Bain Capital
A leading global private investment firm that provides flexible capital solutions and deep sector expertise to drive innovation and operational excellence across its portfolio companies.
Ally Bridge Group
A global healthcare investment management firm specializing in high-impact life science innovation, focusing on bridging the gap between scientific research and financial growth.
Catalio Capital Management
A New York-based firm dedicated to breakthrough biomedical technology, leveraging a vast network of venture partners to support companies across private, public, and credit markets.
What's next for Imperative Care?
With the recent influx of capital, Imperative Care is well-positioned to accelerate its strategic roadmap, focusing on the expansion of its interventional portfolio and the integration of its digital health and robotics initiatives. The company is expected to prioritize the scaling of its commercial operations and the further development of its pipeline, aiming to solidify its footprint in the vascular health market. As the firm moves into this next phase of growth, the focus will likely remain on driving clinical adoption and enhancing the standard of care for patients worldwide, supported by the continued trust of its diverse investor base.
See full Imperative Care company page
